Trial Profile
Prospective, Randomized, Observer-blind, Parallel-group, Multi-center Trial to Assess Efficacy and Safety of Two Different Dilutions of incobotulinumtoxinA (Xeomin) in Patients With Upper Limb Spasticity
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Oct 2016
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Muscle hypertonia
- Focus Therapeutic Use
- 16 Aug 2016 Results (n=572) of this and other two phase 3 trials published in the Drugs (2016).
- 21 Nov 2011 New trial record
- 17 Nov 2011 Results will be presented at the 72nd Annual Assembly of the American Academy of Physical Medicine and Rehabilitation, according to a Merz Pharmaceuticals media release.